LION bioscience AG erweitert Vorstand nach erfolgreich abgeschlossenem Erwerb der SYGNIS Bioscience GmbH & Co. KG
Nach erfolgreichem Abschluss der Kapitalerhöhung im Zusammenhang mit dem Erwerb der SYGNIS Bioscience GmbH & Co. KG hat der Aufsichtsrat der LION bioscience AG mit Wirkung zum 10. Oktober 2006 Dr. Alfred Bach in den Vorstand berufen. Er war zuletzt Vorstand der Axaron Bioscience AG, die auf die Entwicklung von Medikamenten für das zentrale Nervensystem spezialisiert war.
Dr. Alfred Bach wird die Funktion des CEO, Peter Willinger die des CFO der LION bioscience AG übernehmen.
Most read news
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Chronic fatigue syndrome linked to imbalanced microbiome

Blueprint for blueberry improvement: genetic and epigenetic discoveries

New Bacterial Toxins Against Resistant Insect Pests - Scientists from the USA, Mexico, China, and Germany have developed Bt toxins for the management of resistance in European corn borer and other crop pests
In lab tests, new therapy slows spread of deadly brain tumor cells
